Stocks · News reference

Amplitude Therapeutics Partners With Eli Lilly Over Discovery, Development Of taRNA Vaccine Candidates For Infectious Diseases

Aug 19, 2026, 7:32 PMBenzinga Newsdesk

Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LLY

Source: benzinga
Observed: Aug 19, 2026, 7:32 PM
Checked: Aug 19, 2026, 7:32 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 26, 2026, 7:30 PMVandana Singh
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Read original at benzinga
LLY
BenzingaAug 26, 2026, 6:40 PMEvette Mitkov
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Read original at benzinga
LLY
BenzingaAug 26, 2026, 5:04 PMBenzinga Newsdesk
Eli Lilly shares are trading lower. The company reported a real‑world study showing Zepbound cut healthcare costs in adults over 55 with obesity, driven by fewer hospitalizations and ER visits.
Read original at benzinga
LLY
BenzingaAug 26, 2026, 4:58 PMPiero Cingari
Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.
Read original at benzinga
ANET AU BBWI BSX BTCUSD

Amplitude Therapeutics Partners With Eli Lilly Over Discovery, Development Of taRNA Vaccine Candidates For Infectious Diseases

Connected markets

Related headlines

Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs

Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week

Eli Lilly shares are trading lower. The company reported a real‑world study showing Zepbound cut healthcare costs in adults over 55 with obesity, driven by fewer hospitalizations and ER visits.

Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today